JP2020535140A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020535140A5 JP2020535140A5 JP2020516827A JP2020516827A JP2020535140A5 JP 2020535140 A5 JP2020535140 A5 JP 2020535140A5 JP 2020516827 A JP2020516827 A JP 2020516827A JP 2020516827 A JP2020516827 A JP 2020516827A JP 2020535140 A5 JP2020535140 A5 JP 2020535140A5
- Authority
- JP
- Japan
- Prior art keywords
- pericarditis
- composition according
- composition
- months
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023039474A JP7564270B2 (ja) | 2017-09-26 | 2023-03-14 | インターロイキン－１受容体アンタゴニスト融合タンパク質の送達による炎症状態の治療 |
| JP2024110108A JP2024133112A (ja) | 2017-09-26 | 2024-07-09 | インターロイキン－１受容体アンタゴニスト融合タンパク質の送達による炎症状態の治療 |
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762563387P | 2017-09-26 | 2017-09-26 | |
| US62/563,387 | 2017-09-26 | ||
| US201862616819P | 2018-01-12 | 2018-01-12 | |
| US62/616,819 | 2018-01-12 | ||
| US201862625075P | 2018-02-01 | 2018-02-01 | |
| US62/625,075 | 2018-02-01 | ||
| US201862639425P | 2018-03-06 | 2018-03-06 | |
| US62/639,425 | 2018-03-06 | ||
| US201862654291P | 2018-04-06 | 2018-04-06 | |
| US62/654,291 | 2018-04-06 | ||
| US201862691552P | 2018-06-28 | 2018-06-28 | |
| US62/691,552 | 2018-06-28 | ||
| US201862716331P | 2018-08-08 | 2018-08-08 | |
| US62/716,331 | 2018-08-08 | ||
| PCT/US2018/052985 WO2019067639A1 (en) | 2017-09-26 | 2018-09-26 | TREATMENT OF INFLAMMATORY CONDITIONS BY ADMINISTRATION OF INTERLEUKIN-1 RECEPTOR ANTAGONIST FUSION PROTEIN |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023039474A Division JP7564270B2 (ja) | 2017-09-26 | 2023-03-14 | インターロイキン－１受容体アンタゴニスト融合タンパク質の送達による炎症状態の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020535140A JP2020535140A (ja) | 2020-12-03 |
| JP2020535140A5 true JP2020535140A5 (https=) | 2021-11-11 |
| JP7301815B2 JP7301815B2 (ja) | 2023-07-03 |
Family
ID=63858163
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020516827A Active JP7301815B2 (ja) | 2017-09-26 | 2018-09-26 | インターロイキン－１受容体アンタゴニスト融合タンパク質の送達による炎症状態の治療 |
| JP2023039474A Active JP7564270B2 (ja) | 2017-09-26 | 2023-03-14 | インターロイキン－１受容体アンタゴニスト融合タンパク質の送達による炎症状態の治療 |
| JP2024110108A Pending JP2024133112A (ja) | 2017-09-26 | 2024-07-09 | インターロイキン－１受容体アンタゴニスト融合タンパク質の送達による炎症状態の治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023039474A Active JP7564270B2 (ja) | 2017-09-26 | 2023-03-14 | インターロイキン－１受容体アンタゴニスト融合タンパク質の送達による炎症状態の治療 |
| JP2024110108A Pending JP2024133112A (ja) | 2017-09-26 | 2024-07-09 | インターロイキン－１受容体アンタゴニスト融合タンパク質の送達による炎症状態の治療 |
Country Status (12)
| Country | Link |
|---|---|
| US (8) | US11026997B2 (https=) |
| EP (2) | EP3687562B1 (https=) |
| JP (3) | JP7301815B2 (https=) |
| CA (1) | CA3075538A1 (https=) |
| DK (1) | DK3687562T3 (https=) |
| ES (1) | ES3023044T3 (https=) |
| FI (1) | FI3687562T3 (https=) |
| HU (1) | HUE071206T2 (https=) |
| PL (1) | PL3687562T3 (https=) |
| PT (1) | PT3687562T (https=) |
| SI (1) | SI3687562T1 (https=) |
| WO (1) | WO2019067639A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3075538A1 (en) | 2017-09-26 | 2019-04-04 | Regeneron Pharmaceuticals, Inc. | Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein |
| WO2026003765A1 (en) | 2024-06-25 | 2026-01-02 | Kiniksa Pharmaceuticals, Gmbh | Formulations of anti-interleukin 1 receptor 1 antibodies |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060171948A1 (en) * | 2005-02-02 | 2006-08-03 | Weinstein Steven P | Methods of using IL-1 antagonists to reduce C-reactive protein |
| WO2012078101A1 (en) | 2010-12-07 | 2012-06-14 | Swedish Orphan Biovitrum Ab (Publ) | Method for the treatment of il-1 mediated diseases |
| WO2014035361A1 (en) | 2012-08-26 | 2014-03-06 | R-PHARM, CJSC (Closed Joint Stock Company) | IL-1β INHIBITOR COMPOSITION AND USE THEREOF |
| JP6225197B2 (ja) | 2013-02-15 | 2017-11-01 | アール−ファーム・ジョイント・ストック・カンパニーＲ−Ｐｈａｒｍ，Ｊｓｃ | ＩＬ−１β阻害剤組成物およびその使用 |
| WO2015147789A1 (en) | 2014-03-24 | 2015-10-01 | R-Pharm Overseas, Inc. | Human il 1-r1 derived inhibitor of il-1b |
| CA3075538A1 (en) | 2017-09-26 | 2019-04-04 | Regeneron Pharmaceuticals, Inc. | Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein |
-
2018
- 2018-09-26 CA CA3075538A patent/CA3075538A1/en active Pending
- 2018-09-26 FI FIEP18786587.8T patent/FI3687562T3/fi active
- 2018-09-26 PL PL18786587.8T patent/PL3687562T3/pl unknown
- 2018-09-26 WO PCT/US2018/052985 patent/WO2019067639A1/en not_active Ceased
- 2018-09-26 PT PT187865878T patent/PT3687562T/pt unknown
- 2018-09-26 HU HUE18786587A patent/HUE071206T2/hu unknown
- 2018-09-26 DK DK18786587.8T patent/DK3687562T3/da active
- 2018-09-26 US US16/143,391 patent/US11026997B2/en active Active
- 2018-09-26 ES ES18786587T patent/ES3023044T3/es active Active
- 2018-09-26 SI SI201831227T patent/SI3687562T1/sl unknown
- 2018-09-26 EP EP18786587.8A patent/EP3687562B1/en active Active
- 2018-09-26 JP JP2020516827A patent/JP7301815B2/ja active Active
- 2018-09-26 EP EP25150543.4A patent/EP4541367A3/en active Pending
-
2021
- 2021-03-22 US US17/208,409 patent/US20210283224A1/en not_active Abandoned
- 2021-11-16 US US17/527,956 patent/US11464830B2/en active Active
-
2022
- 2022-09-02 US US17/929,458 patent/US11944666B2/en active Active
- 2022-09-02 US US17/929,572 patent/US20220409699A1/en not_active Abandoned
-
2023
- 2023-03-14 JP JP2023039474A patent/JP7564270B2/ja active Active
- 2023-05-05 US US18/313,134 patent/US11844765B2/en active Active
-
2024
- 2024-05-22 US US18/671,801 patent/US12201673B2/en active Active
- 2024-07-09 JP JP2024110108A patent/JP2024133112A/ja active Pending
-
2025
- 2025-07-23 US US19/278,317 patent/US20250345396A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7546599B2 (ja) | 関節炎性疾患の組み合わせ療法 | |
| JP2019535734A5 (https=) | ||
| TW201936600A (zh) | 以ccr6或cxcr2之拮抗劑治療廣泛性膿疱型乾癬之方法 | |
| EA034864B1 (ru) | Способ лечения эозинофильной астмы со степенью тяжести от умеренной до тяжёлой | |
| US20250345396A1 (en) | Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein | |
| JP2020535140A5 (https=) | ||
| BR112021008688A2 (pt) | tratamento para arterite de célula gigante | |
| KR101030416B1 (ko) | 류마티스성 관절염의 치료 | |
| JP2005526022A5 (ja) | 関節リウマチの処置 | |
| AU763575B2 (en) | Use of soluble tumor necrosis factor receptor for treatment heart failure | |
| RU2828044C2 (ru) | Комбинированное лечение артрита | |
| Casado et al. | 4CPS-132 Indirect treatment comparison of anti-calcitonin gene related peptide pathway antibodies in chronic migraine | |
| JPWO2023097259A5 (https=) | ||
| TW202436330A (zh) | 類升糖素胜肽-2(glp-2)類似物及其用於治療短腸症候群(sbs)之醫藥用途 | |
| BR122025027043A2 (pt) | USO DE ANTICORPO ANTI-OSMRbeta | |
| HK40035543B (en) | Treatment of recurrent idiopathic pericarditis by delivery of interleukin-1 receptor antagonist fusion protein | |
| HK40035543A (en) | Treatment of recurrent idiopathic pericarditis by delivery of interleukin-1 receptor antagonist fusion protein |